Investors

Half-year liquidity contract statement signed between Median Technologies and AUREL BGC

10 July 2018, Sophia Antipolis, France

Under the liquidity contract entrusted by Median Technologies to AUREL BGC, the following resources were listed in the liquidity account at June 30, 2018:

  • € 131,204.47
  • 31,040 shares

For information, at December 31, 2017, the following resources were listed in the liquidity account:

  • € 205,848.52
  • 20,981 shares

About Median Technologies

Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT).

Contacts

Median Technologies

Emmanuelle Leygues
Head of Corporate Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com

Actifin  (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP  (Press)

Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com